Literature DB >> 18165772

The impact of left ventricular systolic dysfunction on survival after renal transplantation.

Andrew Siedlecki1, Margaret Foushee, John J Curtis, Robert S Gaston, Gilbert Perry, Ami E Iskandrian, Angelo M de Mattos.   

Abstract

BACKGROUND: Gated single photon emission computed tomography (SPECT) provides information on myocardial perfusion and left ventricular ejection fraction (LVEF), which correlates with risk of cardiac events in patients with known or suspected coronary artery disease (CAD). We hypothesize that decreased LVEF at time of renal transplant evaluation is an independent risk factor for cardiac death and nonfatal events after transplant. METHODS AND
RESULTS: A total of 653 recipients of renal allografts between 1998 and 2005 had stress SPECT imaging before transplantation. One hundred and nineteen (18%) patients had left ventricular (LV) systolic dysfunction (LVEF </=45%). The patients with LV dysfunction differed from the patients with normal LVEF having a higher proportion of males, smokers, left ventricular hypertrophy, previous left heart catheterization, and higher exposure to dialysis. During a mean follow-up of 3.01+/-1.86 years postrenal transplant, 66 patients died and 67 additional patients experienced at least one nonfatal cardiac-related complication. Patients with LV systolic dysfunction were at considerably higher risk for cardiac complications (hazard ratio [HR] 1.8, P=0.01) and all-cause mortality (HR 2.0, P=0.01) after transplantation. By multivariate analysis, LV systolic dysfunction was associated with a 5-fold increase in the cardiac mortality risk, a 2-fold increase in all-cause mortality risk, and a 70% increase in posttransplant cardiac complications.
CONCLUSIONS: Systolic dysfunction is associated with increased risk for overall and cardiac-related death and nonfatal events after renal transplantation, an association independent of ischemic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18165772     DOI: 10.1097/01.tp.0000295748.42884.97

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.

Authors:  Srinivasan Mukundan; Michael L Steigner; Li-Li Hsiao; Sayeed K Malek; Stefan G Tullius; Matthew S Chin; Andrew M Siedlecki
Journal:  Am J Kidney Dis       Date:  2016-01-16       Impact factor: 8.860

2.  Early cardiac dysfunction in pediatric patients on maintenance dialysis and post kidney transplant.

Authors:  Rossana Malatesta-Muncher; Janaka Wansapura; Michael Taylor; Diana Lindquist; Kan Hor; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2012-02-23       Impact factor: 3.714

Review 3.  Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies.

Authors:  Krista L Lentine; Frank P Hurst; Rahul M Jindal; Todd C Villines; Jeffrey S Kunz; Christina M Yuan; Paul J Hauptman; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2009-09-23       Impact factor: 8.860

4.  Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study.

Authors:  Attila Kovács; Mihály Tapolyai; Csilla Celeng; Edit Gara; Mária Faludi; Klára Berta; Astrid Apor; Andrea Nagy; András Tislér; Béla Merkely
Journal:  Int J Cardiovasc Imaging       Date:  2014-07-08       Impact factor: 2.357

Review 5.  Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.

Authors:  Abhilash Koratala; Amir Kazory
Journal:  Dis Markers       Date:  2017-06-18       Impact factor: 3.434

Review 6.  Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease.

Authors:  Navdeep K Bhatti; Keyvan Karimi Galougahi; Yehuda Paz; Tamim Nazif; Jeffrey W Moses; Martin B Leon; Gregg W Stone; Ajay J Kirtane; Dimitri Karmpaliotis; Sabahat Bokhari; Mark A Hardy; Geoffrey Dube; Sumit Mohan; Lloyd E Ratner; David J Cohen; Ziad A Ali
Journal:  J Am Heart Assoc       Date:  2016-08-04       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.